Page 118 - 2018_09-Mondo

a
Plasma Cell DIsorders
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan- prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Jesús F. San-Miguel,1 Maria-Asunción Echeveste Gutierrez,2 Ivan Špicka,3 María-Victoria Mateos,4 Kevin Song,5 Michael D. Craig,6 Joan Bladé,7 Roman Hájek,8 Christine Chen,9 Alessandra Di Bacco,10 Jose Estevam,10 Neeraj Gupta,10 Catriona Byrne,10 Vickie Lu,10 Helgi van de Velde10*
)
Haematologica 2018 Volume 103(9):1518-1526
Ferrata Storti Foundation
1Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA),
El Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain; 2Hospital Universitario Donostia, San Sebastián, Spain; 31st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic; 4Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain; 5Division of Hematology, University of British Columbia, Vancouver, BC, Canada; 6Department of Medicine, West Virginia University, Morgantown, WV, USA; 7Department of Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain;
8Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, Ostrava University, Czech Republic; 9Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, ON, Canada; 10Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and 11Winship Cancer Institute of Emory University, Atlanta, GA, USA
*Current affiliation: Sanofi, Cambridge, MA, USA
ABSTRACT
This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in elderly, transplant-ineligi- ble patients with newly diagnosed multiple myeloma. Primary phase I objectives were to determine the safety and recommended phase II dose of ixazomib-melphalan-prednisone. The primary phase II objective was to determine the complete plus very good partial response rate. In phase I, patients were enrolled to 4 arms investigating weekly or twice-weekly ixazomib (13 28-day cycles or nine 42-day cycles) plus melphalan-prednisone. In phase II, an expansion cohort was enrolled at the recommended phase II ixazomib dose. Of the 61 patients enrolled, 26 received the recommended phase II dose (ixazomib 4.0 mg [days 1, 8, 15] plus melphalan-prednisone 60 mg/m2 [days 1-4], 28-day cycles). Of the 61 enrolled patients, 36 (13 of 26 in the recommended phase II dose cohort) received single-agent ixazomib maintenance (days 1, 8, 15; 28-day cycles). In phase I, 10/38 patients reported dose-limiting toxici- ties in cycle 1, including grade 3 and/or 4 neutropenia (n=6) and thrombocytopenia (n=4). Complete plus very good partial response rate was 48% (48% at recommended phase II dose), including 28% (22%) complete response or better; responses deepened during maintenance in 34% (33%) of evaluable patients. After median follow up of 43.6 months, median progression-free survival was 22.1 months. Adverse events were mainly hematologic events, gastrointestinal events, and peripheral neuropathy. This study demonstrates the feasibility, tolerability, and activity of ixazomib-melphalan-prednisone induction and single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma patients. clinicaltrials.gov identifier 01335685.
and Sagar Lonial11
y
Correspondence:
sanmiguel@unav.es
Received: February 2, 2018. Accepted: June 25, 2018. Pre-published: June 28, 2018.
doi:10.3324/haematol.2017.185991
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/103/9/1518
©2018 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
ARTICLE
1518
haematologica | 2018; 103(9)